This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Computational Biology Market Is Expected To Reach USD 2,937.3 Million Globally In 2018: Transparency Market Research

ALBANY, New York, May 7, 2013 /PRNewswire/ --

According to a new market report published by Transparency Market Research ( http://www.transparencymarketresearch.com), " Computational Biology (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development)  -  Global Industry Analysis, Size, Sha re, Growth, Trends and Forecast, 2012  -  2018, " in 2011, the global computational biology market was valued at USD 760 million and is expected to grow at a CAGR of 21.3% from 2012 to 2018 to reach an estimated value of USD 2,937.3 million by 2018.

Browse the full report at  http://www.transparencymarketresearch.com/computational-biology.html

Computational biology uses sequencing, databases and supercomputers for analysis and algorithm formation to predict the molecules that can be taken for drug identification and lead optimization. Setbacks in drug discovery with absence of potential blockbusters in the market coupled with cost containment issues faced by major drug manufacturers has compelled the major players to shift their focus to newer methods of drug discovery in order to help accelerate the drug development process and bring down R&D expenditure.

The drug discovery market is the fastest growing segment and is anticipated to grow at a CAGR of more than 25% from 2012 to 2018. The use of computational biology for drug discovery now offers manufacturers a method to reduce R&D expenditure and to reduce chances of late stage failure of drug candidates. Computational software and simulation tools are being used in various stages of drug discovery to minimize the future risks of drug failure in later stages of drug development.

Related & Recently Published Reports by Transparency Market Research

http://www.transparencymarketresearch.com/peripheral-vascular-devices-market.html

http://www.transparencymarketresearch.com/nephrology-and-urology-devices-market.html

http://www.transparencymarketresearch.com/x-ray-market.html

http://www.transparencymarketresearch.com/medical-robotic-systems.html

http://www.transparencymarketresearch.com/breast-pumps-market.html

Geographically, North America constituted the largest market in the year 2011. This has been partly due to an encouraging environment for this field created by the US FDA and intense R&D efforts in this region by major pharmaceutical players. The U.S. Federal Government has been supportive through provision of funds for R&D; additionally, academic centres use modelling and simulation for drug discovery. However, Asia is expected to be the fastest growing region due to the emergence of many small regional players as well as lower operating costs as compared to the developed markets.

The global computational biology market is predominantly ruled by major players namely Schrödinger, Accelrys, Certara, Compugen, Simulation Plus, Entelos and others. The market is oligopolistic and these major players account for almost 80% of the market share.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs